Pinnacle Private Wealth LLC trimmed its position in Moderna, Inc. (NASDAQ:MRNA – Get Rating) by 6.7% in the second quarter, Holdings Channel reports. The firm owned 4,233 shares of the company’s stock after selling 306 shares during the quarter. Pinnacle Private Wealth LLC’s holdings in Moderna were worth $605,000 as of its most recent SEC filing.
Other hedge funds have also bought and sold shares of the company. Standard Family Office LLC acquired a new position in shares of Moderna during the fourth quarter valued at approximately $25,000. AllSquare Wealth Management LLC acquired a new position in Moderna during the 1st quarter worth $26,000. IFS Advisors LLC acquired a new position in Moderna during the 4th quarter worth $27,000. Lake Point Wealth Management bought a new position in shares of Moderna during the 4th quarter worth about $27,000. Finally, Bivin & Associates Inc. bought a new position in shares of Moderna during the 4th quarter worth about $29,000. 60.76% of the stock is currently owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
MRNA has been the topic of a number of analyst reports. Argus lowered their target price on shares of Moderna from $180.00 to $150.00 and set a “buy” rating on the stock in a research note on Wednesday, September 14th. Morgan Stanley cut their price objective on shares of Moderna from $199.00 to $197.00 and set an “equal weight” rating on the stock in a report on Thursday, August 4th. Deutsche Bank Aktiengesellschaft upgraded shares of Moderna from a “hold” rating to a “buy” rating and increased their price objective for the company from $155.00 to $165.00 in a report on Wednesday, September 7th. Finally, SVB Leerink increased their price objective on shares of Moderna from $70.00 to $77.00 and gave the stock an “underperform” rating in a research report on Monday, August 1st. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat.com, Moderna currently has an average rating of “Hold” and a consensus price target of $211.08.
Moderna Trading Down 0.5 %
Moderna (NASDAQ:MRNA – Get Rating) last announced its quarterly earnings data on Wednesday, August 3rd. The company reported $5.24 EPS for the quarter, beating the consensus estimate of $4.73 by $0.51. The business had revenue of $4.73 billion during the quarter, compared to analyst estimates of $3.95 billion. Moderna had a return on equity of 94.76% and a net margin of 61.12%. The company’s revenue for the quarter was up 8.7% on a year-over-year basis. During the same quarter last year, the firm posted $6.46 earnings per share. As a group, sell-side analysts predict that Moderna, Inc. will post 26.41 EPS for the current year.
Insider Buying and Selling
In other news, CEO Stephane Bancel sold 40,000 shares of Moderna stock in a transaction dated Thursday, June 30th. The stock was sold at an average price of $143.21, for a total transaction of $5,728,400.00. Following the transaction, the chief executive officer now directly owns 5,411,946 shares of the company’s stock, valued at approximately $775,044,786.66. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In other news, Director Noubar Afeyan sold 10,000 shares of the company’s stock in a transaction dated Wednesday, September 7th. The shares were sold at an average price of $129.68, for a total value of $1,296,800.00. Following the transaction, the director now directly owns 2,427,209 shares in the company, valued at $314,760,463.12. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Stephane Bancel sold 40,000 shares of the stock in a transaction dated Thursday, June 30th. The stock was sold at an average price of $143.21, for a total transaction of $5,728,400.00. Following the transaction, the chief executive officer now owns 5,411,946 shares in the company, valued at $775,044,786.66. The disclosure for this sale can be found here. In the last ninety days, insiders sold 598,048 shares of company stock worth $94,864,342. 17.30% of the stock is owned by corporate insiders.
Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines.
- Get a free copy of the StockNews.com research report on Moderna (MRNA)
- Why Does Tesla Stock Remain Resilient?
- Is Costco’s Post-Earnings Price Weakness A Good Time To Buy?
- 2 Semiconductor Stocks To Watch For Reversals
- Are Layoffs At A Small-Cap Tech A Bellwether For Housing Stocks?
- Will Crowdstrike Get A Boost From Increased EPS Guidance?
Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.